Aussie court rules against Sanofi on Taxotere; Novo profits fall short;

 @FiercePharma: Who's the lead dog in Sanofi-Genzyme talks? Story | Follow @FiercePharma

> Sanofi-Aventis failed to block two generic drug manufacturers from selling a copy of the cancer drug Taxotere in Australia, as a federal court judge refused to bar the sale of the generics. Report

> Danish drugmaker Novo Nordisk reported a smaller-than-forecast rise in fourth-quarter profit, held back partly by increased costs, and raised 2011 profit guidance. News

> Cancer biomarker offers clues into when it will spread. Article

> Urine test may detect brain tumor biomarkers. Story 

> Danes begin biggest-ever resveratrol study. Report 

> Purdue Pharma launched an opioid-based continual-release analgesic for the treatment of chronic pain, in patch form. Article

> Biogen Idec reported that its fourth-quarter profit tumbled 21 percent, citing restructuring charges and rising expenses that outweighed the sales of key drugs. Report

> Glenmark Pharmaceuticals reported a 17 percent rise in consolidated quarterly net profit, largely in line with street estimates, on robust growth in domestic formulations business. Story

Biotech News

@FierceBiotech: Orexigen crashes after FDA demands pre-approval Contrave study. Item | Follow @FierceBiotech

@JohnCFierce: Just got off the phone with Pfizer worldwide R&D chief Mikael Dolsten. Pfizer is looking for central Cambridge facility to consolidate R&D. Follow @JohnCFierce

> Sanofi GLP-1 diabetes drug edges Byetta in Phase III study. Article 

> Reports: Sanofi and Genzyme agree on upper $70s, wrangle over cash vs CVR. News 

> Can Orexigen fund a major new cardio study of Contrave? Story

> Cambridge, MA a rare winner in Pfizer R&D gambit. News

Drug Delivery

> Plankton inspires stealth nano-armor for drug delivery. Story

> Gold nanoshells successfully zap glioma tumors. Report 

> Particle pretends it's iron to slip through blood-brain barrier. News

> C Dots approved for trials as imaging agent. Report 

Medical Devices

> Earnings: Covidien sees devices sales up 11%, Bard reports positive results. News 

> AnalizaDx looking for cancer-screening partner. Article 

> Teleflex switches CEOs. Story 

> J&J pays out $482M in patent infringement case. Report

> Kieran Gallahue to become new CareFusion CEO. Item 

> Volcano sees mixed decision in dispute with St. Jude unit. Story 

And Finally... Senate Republicans, seizing on a court ruling that the healthcare overhaul is unconstitutional, will push ahead with a vote to repeal the legislation; it's unlikely to succeed. Report

Suggested Articles

After years of having first-line liver cancer market to itself, Bayer’s Nexavar is getting major competition from Roche's Tecentriq.

Most of the recent enthusiasm around AbbVie’s new drugs has centered on Skyrizi and Rinvoq, but elagolix wants a piece of the spotlight, too.

During David Loew's tenure, Sanofi Pasteur bought Protein Sciences, whose recombinant technology is being applied to a COVID-19 vaccine.